Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
WT1 DNA vaccination by intramuscular electroporation in AML and CML
ISRCTN62678383Phase 2Completed
- Sponsor
- University Hospital Southampton NHS Foundation Trust
- Start
- Nov 2010
- Modality
- Prophylactic Vaccines → Vaccines & Immunotherapeutics, DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics
01
Overview
Phase 2, open-label trial of WT1 DNA vaccine in acute myeloid leukemia (AML) and chronic myelogenous leukemia (CML) (2 arms), sponsored by University Hospital Southampton NHS Foundation Trust. Primary endpoints: Molecular response of BCR-ABL transcripts and Time to disease progression. Started Nov 2010; status: completed.
02
Drugs
WT1 DNA vaccine
03
Conditions
acute myeloid leukemia (AML)chronic myelogenous leukemia (CML)
Beyond the preview
Go deeper on ISRCTN62678383.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN62678383.